Clofibric-acid and GW-4064, as PPAR and FXR agonists, respectively, demonstrate significant anti-inflammatory and metabolic regulatory effects, indicating their potential in managing COPD-related inflammation and metabolic dysregulation. This evidence concerns the gene NR1H4 and chronic obstructive pulmonary disease.